In tumour angiogenesis this balance falls in favour of VEGF, but in studies that followed the targeted delivery of Sema3A, tumour angiogenesis was inhibited and vessels regained a functional morphology.68,69. The gene discussed is VEGFA; the disease is neoplasm.